Brind.

Celldex Therapeutics and Zacks Medical operated within the biomedical sector and underperformed the broader market index on August 8, 2025.

1 report, 1 independent Updated Aug 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Celldex Therapeutics and Zacks Medical operated within the biomedical sector and underperformed the broader market index on August 8, 2025.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • ZacksCelldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0